ReviewClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association2022
Expert Panel Review on Nonalcoholic Fatty Liver Disease in Persons With Human Immunodeficiency Virus.
Review in Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Uncovering the NAFLD burden in people living with HIV from high- and middle-income nations: a meta-analysis with a data gap from Subsaharan Africa.Journal of the International AIDS Society · 2023Pooled it
- Regional variation in NAFLD prevalence and risk factors among people living with HIV in Europe: a meta-analysis.Frontiers in public health · 2023Pooled it
- Semaglutide improves markers of cardiovascular risk in people with HIV.AIDS (London, England) · 2026Trial
- Effects of Semaglutide on Muscle Structure and Function in the SLIM LIVER Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Trial
- Trial
- Predictors of Liver Steatosis Progression Among People Living With HIV in Low- and Middle-Income Countries: A Multicentre Longitudinal Study.Journal of the International AIDS Society · 2026Article
- Older people living with HIV: a population with high prevalence and severity of metabolic dysfunction-associated steatotic liver disease ‒ A cross-sectional study.The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases · 2026Article
- Non-Hispanic Black Persons With HIV Have a Lower Risk of Metabolic Dysfunction-Associated Steatotic Liver Disease and Clinically Significant Fibrosis Compared to Non-Hispanic White and Hispanic Individuals.Open forum infectious diseases · 2026Article
- Metabolic dysfunction-associated steatotic liver disease in people living with HIV: mechanisms, diagnosis, and management.Frontiers in immunology · 2026Review
- Liver-specific Expression of HIV-1 Viral Protein R Causes Hepatic Steatosis and Glucose Intolerance in Male Mice.Journal of the Endocrine Society · 2025Article
- Metabolic dysfunction-associated liver disease predicts incident liver fibrosis in people with HIV mono-infection: A cohort study.HIV medicine · 2025Observational
- Noninvasive Markers of Hepatic Steatosis and Fibrosis Following Integrase Strand-Transfer Inhibitor Initiation in Women With HIV.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Article
- Metabolic dysfunction-associated steatotic liver disease in people with HIV.Current opinion in HIV and AIDS · 2025Review
- Prevalence of metabolic syndrome in people living with HIV and its multi-organ damage: a prospective cohort study.BMC infectious diseases · 2025Article
- Pathogenesis of HIV-Associated Metabolic Syndrome and Clinical Management Recommendations.International journal of general medicine · 2025Review
- Sex Differences in Metabolic Disorders of Aging and Obesity in People with HIV.Current HIV/AIDS reports · 2024Review
- Transgender Women with HIV Demonstrate Unique Non-Alcoholic Fatty Liver Disease Profiles.Transgender health · 2024Article
- Cardiometabolic Characteristics of Obesity Phenotypes in Persons With HIV.Open forum infectious diseases · 2024Article
- Liver Steatosis is Prevalent in Lean People With HIV and Associated With Exposure to Antiretroviral Treatment-A Cross-sectional Study.Open forum infectious diseases · 2024Article
- Prevalence of steatotic liver disease, MASLD, MetALD and significant fibrosis in people with HIV in the United States.Alimentary pharmacology & therapeutics · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Nonalcoholic fatty liver disease (NAFLD) affects 25% of adults in the general population and is a disease spectrum ranging from steatosis to nonalcoholic steatohepatitis (NASH) to end-stage liver disease. NAFLD is an independent risk factor for cardiovascular disease, diabetes mellitus, and all-cause mortality, and NASH cirrhosis is a frequent indication for liver transplantation. In persons with human immunodeficiency virus (PWH), chronic liver disease is the second leading cause of non-human immunodeficiency virus-related mortality. Between 20% and 63% of PWH have NASH, and 14% to 63% have NASH with fibrosis. However, little is known about the optimal diagnostic strategies, risk factors for, and treatment of NAFLD in PWH. Here, we review current data on and identify knowledge gaps in the epidemiology, pathophysiology, diagnosis, and management of NAFLD in PWH and highlight priorities for research.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.